This number is significantly low when compared to the sales of currently marketed RSV vaccines Arexvy and Abrysvo, marketed by pharma giants GSK and Pfizer, respectively. The softer sales ...

In its update posted this morning, GSK revealed that sales of its Arexvy vaccine came in at £1.24 billion ($1.57 billion) in 2023, including £529 million ($671 million) from the fourth quarter.

Sales of GSK's respiratory syncytial virus (RSV) vaccine Arexvy slumped 72% in the third quarter of this year, as narrower recommendations on its use in the US started to have an effect.

Chairman & CEO. “Faisal has a proven track record in integrating cutting-edge science with practical, evidence-base PHILADELPHIA, October 24, 2024--New data for AREXVY, GSK’s RSV vaccine ...

Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...

Rapid antigen-based testing was quickly embraced for its ease of use and speed; results are available within an unprecedented 30 min, potentially at the point of care, and without the requirement ...

IPC Indice de Precios Y Cotizaciones 54,160.11 94.39 0.17% ...